Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending January 2016. The report serves as a notification to the market regarding the Company's total voting rights and capital structure in conformity with Disclosure and Transparency Rule (DTR) 5.6.1R.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on capital structure details as of December 31, 2015:
- Issued Share Capital: 5,358,508,156 Ordinary Shares of 25p each.
- Treasury Shares: 491,515,950 Ordinary Shares.
- Total Voting Rights: 4,866,992,206.
Material Changes
The filing text does not provide a clear value for material changes versus the prior comparable period. The document is a static notification of share capital and voting rights as of the specified date.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is a regulatory disclosure regarding shareholder voting rights calculations under the Financial Conduct Authority's rules.
Investor Verification Checklist
- Verify the total number of voting rights (4,866,992,206) for compliance with DTR 6.4.2R notification thresholds.
- Confirm the count of treasury shares (491,515,950) held as of December 31, 2015.
- Review the Company's annual report (Form 20-F) for comprehensive financial performance data not included in this filing.